

ASTCT + EBMT

7TH INTERNATIONAL

RELAPSE

After Transplant and Cellular Therapy (HSCT²)

CONFERENCE

ASTCT[®]
American Society for
Transplantation and Cellular Therapy

EBMT

14-15 November 2025

Madrid, Spain

20
25

WORD OF WELCOME

The American Society for Transplantation and Cellular Therapy (ASTCT) and The European Society for Blood and Marrow Transplantation (EBMT) are proud to present the 7th ASTCT+EBMT International Conference on Relapse after Transplant and Cellular Therapy, taking place November 14–15 in Madrid, Spain.

Hematopoietic stem cell transplantation and cellular therapies (HSCT²) remain life-saving treatment options for many hematologic malignancies and select solid tumors. However, relapse and disease progression continue to be the leading causes of treatment failure following both allogeneic and autologous hematopoietic stem cell transplantation (HSCT), as well as CAR T-cell therapy.

Since the first symposium over 12 years ago, there has been tremendous progress in understanding and managing relapse—culminating in the development of therapies specifically approved to prevent or treat relapse after HSCT and cellular therapies.

This year's conference will bring together internationally recognized experts from across the scientific spectrum, including basic, translational, and clinical investigators. The program will feature formal presentations, interactive panel discussions, and dedicated oral and poster sessions, offering investigators the opportunity to showcase their latest research. As in previous years, selected abstracts will be highlighted through oral presentations during the meeting.

Scientific Programme Committee:

- **Nicolaus Kröger** | *Founding member*
- **Alan Wayne** | *Founding member*
- **Sergio Giral** | *Founding member*
- **Michael Bishop** | *Founding member*
- **Charles Craddock**
- **Victoria Potter**
- **Nirali Shah**
- **Saar Gill**
- **Mette Hanzenberg**
- **Chris Hourigan**
- **Anna Sureda** | *EBMT President*
- **Corey Cutler** | *ASTCT President*

For further information, please contact education.events@ebmt.org

Friday, 14 November 2025

08:00 - 08:15	Welcome & Introduction Chairs: Corey Cutler (US) & Mette Hazenberg (NL)	
08:15 - 09:00	Keynote Lecture I: Relapse landscape and mechanism early and late Chairs: Corey Cutler (US) & Mette Hazenberg (NL) Probing leukaemia-host co-evolution in relationship to response and resistance to allo-HSCT	Catherine J. Wu (US)
09:00 - 10:30	Session I: Relapse after Allo Chairs: Victoria Potter (UK) & Luca Vago (IT)	
09:00 - 09:15	T-cell immunology predicting relapse post-allogeneic stem cell transplant	Mahasweta Gooptu (US)
09:15 - 09:30	Immunological prevention of relapse	Pramila Krishnamurthy (UK)
09:30 - 09:45	Personalised / Precision approaches to target immune escape after allogeneic stem cell transplant	
09:45 - 10:00	Case Presentation: Mutation clearance predicts relapse in accelerated-phase myelofibrosis after transplantation	Luca Vago (IT)
10:00 - 10:15	Case Presentation: A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in R/R AML/MDS	Nicolaus Kröger (DE)
10:15 - 10:30	Panel discussion	Aleksandra Filipovic (US)
10:30 - 11:00	Coffee Break	
11:00 - 12:00	Session II: Mechanisms of Relapse after auto-HCT in MM and Lymphoma Chair: Nicolaus Kröger (DE)	
11:00 - 11:15	Case Presentation: Treatment of MDS relapse after allogeneic stem cell transplantation (alloSCT): Significantly reduced relapse incidence after donor change for the second alloSCT	Giuliano Filippini (DE)
11:15 - 11:30	Case Presentation: Single-cell transcriptomics reveals early dynamic immune trajectories associated with clinical outcome following allogeneic stem cell transplantation	Kriti Verma (UK)
11:30 - 11:50	Checkpoint inhibitors in Hodgkin's Lymphoma	Alison Moskowitz (US)
11:50 - 12:00	Panel discussion	
12:00 - 13:00	Lunch Break	

13:00 - 14:15

Session III: Relapse after CAR

Chair: Nirali N. Shah (US)

Biology of antigen escape

13:00 - 13:15

Biology of antigen escape

Kara Davis (US)

13:15 - 13:25

Case presentation: Treatment of antigen escape, including lineage switch

Sara Ghorashian (UK)

13:25 - 13:40

Panel discussion

Advances in combinatorial antigen targeting strategies

13:40 - 13:55

Advances in combinatorial antigen targeting strategies

Christian Seitz (DE)

13:55 - 14:05

Case Presentation:

Development of a CAR-NK Therapy Regulated by the KLRC1 Locus as a New Platform for More Selective Control of Acute Myeloid Leukemia

Asunción Borrego (US)

14:05 - 14:15

Panel discussion

14:15 - 14:45

Coffee Break

14:45 - 16:00

Best Abstracts Session

Chairs: Michael Bishop (US)

14:45 - 14:55

Case Presentation:

Exploiting transcriptional and metabolic vulnerabilities to counteract leukemia immune escape after transplantation

Annalisa Tameni (IT)

14:55 - 15:05

Case Presentation:

Base-editing Human Hematopoietic Stem Cells to Enable Venetoclax Post-Transplant Maintenance Therapy for AML

Joanne Baek (US)

15:05 - 15:15

Case Presentation:

Naïve T Cell-Depleted Haploidentical HCT with Selected Blinatumomab for Paediatric Hematologic Malignancies Relapsed after Prior HCT

Rebecca Epperly (US)

15:15 - 15:25

Case Presentation:

Phenotypes and TCR repertoires of leukaemia cutis-associated T cells

Livius Penter (DE)

15:25 - 15:35

Case Presentation:

Trials in Progress: A Phase I/2 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects with Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Acute Lymphoblastic Leukemia Who Are Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

Chrystal Louis (US)

15:35 - 15:45

Case Presentation:

Real-world outcomes of adult B-ALL patients who experience relapsed or refractory disease following brexucabtagene autoleucel

Gregory Roloff (US)

15:45 - 16:00

Q&A

16:00 - 17:30

Welcome Reception + Poster Session

Saturday, 15 November 2025

08:00 - 08:45	Keynote Lecture II: Relapse after CAR T Chair: Nicolaus Kröger (DE) Relapse after CAR T	Saar Gill (US)
08:45 - 10:00	Session IV: MRD/new technologies for monitoring MRD (CTDNA) Chair: Chris Hourigan (US)	
08:45 - 09:05	Peripheral Residual Disease Monitoring using Mass Spectrometry and Next-Gen Methods in Transplant-Eligible Patients with Multiple Myeloma	Bruno Paiva (ES)
09:05 - 09:25	Computational and immune-integrative approaches to optimise MRD detection after allogeneic transplant	Sylvie Freeman (UK)
09:25 - 09:45	Pre and Post transplant NGS-MRD in patients allografted for acute leukaemia	Lori Muffly (US)
09:45 - 10:00	Panel discussion	
10:00 - 10:30	Coffee Break	
10:30 - 11:45	Session V (part I): Preventing Relapse in Patients Allografted for AML Chairs: Charles Craddock (UK) & Sergio Giralt (US)	
10:30 - 10:45	Current / Future Trials of the BMT CTN Group Aimed at Preventing Relapse	Yi-Bin Chen (US)
10:45 - 11:00	Current / Future Trials of the UK IMPACT Group Aimed at Preventing Relapse	Victoria Potter (UK)
11:00 - 11:15	Current / Future Trials of the German Transplant Group Aimed at Preventing Relapse	Thomas Schroeder (DE)
11:15 - 11:45	Panel discussion	
11:45 - 12:00	Break	
12:00 - 13:00	Session V (part II): Preventing Relapse after CAR-T cell Therapy Chairs: Charles Craddock (UK) & Victoria Potter (UK)	
12:00 - 12:10	Optimising pre-infusion strategies	Michael Jain (US)
12:10 - 12:20	How to modify the cellular inoculum to increase persistence	Claire Roddie (UK)
12:20 - 12:30	Post-infusion interventions	Rebecca Gardner (US)
12:30 - 13:00	Discussion	
13:00 - 14:00	Lunch Break	
14:00 - 15:00	Session VI: Microbiome, tumour immunology and relapse Chair: Mette Hazenberg (NL)	
14:00 - 14:15	Long-distance microbial mechanisms impacting cancer immunosurveillance	Camille Bigenwald (FR)
14:15 - 14:30	Intestinal microbiota, cellular therapy and relapse: mechanisms and implications	Melody Smith (US)
14:30 - 14:45	Approaches to protect the microbiome from damage and its association with relapse	Hendrik Poeck (DE)
14:45 - 15:00	Panel discussion	

ASTCT + EBMT

7TH INTERNATIONAL

RELAPSE

After Transplant and Cellular Therapy (HSCT²)

CONFERENCE

ASTCT[®]
American Society for
Transplantation and Cellular Therapy

EBMT

14-15 November 2025

Madrid, Spain

20
25

15:00 - 16:05

Session VII: Maintenance post Cell Therapy

Chair: Saar Gill (US)

15:00 - 15:15

Post-transplant TCR engineered T cells to maintain remission and prevent relapse

15:15 - 15:30

DLI for prevention of relapse post alloSCT

15:30 - 15:45

Post-transplant maintenance with FLT3 inhibitors; all the news that's fit / not fit to print

15:45 - 16:05

Panel discussion

Marie Bleakley (US)

Christoph Schmid (DE)

Mark Levis (US)

16:05 - 16:30

Concluding Remarks

Nicolaus Kröger (DE) & Michael Bishop (US)

For further information, please contact education.events@ebmt.org

ASTCT + EBMT

7TH INTERNATIONAL

RELAPSE

After Transplant and Cellular Therapy (HSCT²)

CONFERENCE

ASTCT[®]
American Society for
Transplantation and Cellular Therapy

EBMT

14-15 November 2025

Madrid, Spain

20
25

WITH THANKS TO OUR SPONSORS

Bronze Partners



For further information, please contact education.events@ebmt.org